Catheter Ablation vs Drug Therapy in Patients With Atrial Fibrillation and Nonmodifiable Recurrence Risk Factors

Are nonmodifiable recurrence risk factors (NMRRFs) associated with differences in benefit of catheter ablation compared with drug therapy in patients with atrial fibrillation (AF)?In this subanalysis of 2185 patients enrolled in the Catheter Ablation vs Anti-Arrhythmic Drug Therapy for Atrial Fibrillation randomized clinical trial, catheter ablation reduced the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest in patients with fewer than 3 NMRRFs. However, it showed no significant benefit of the primary composite end point in patients with 3 or more NMRRFs.The findings suggest that catheter ablation could improve the cardiovascular prognosis for individuals with AF with fewer than 3 NMRRFs, laying the foundation for more personalized AF management and research in the field.

Corresponding Authors: Changsheng Ma, MD, Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chao Yang District, Beijing 100029, China (chshma@vip.sina.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.